CHMP recommends EU approval of Roche’s fixed-duration Columvi for large B-cell lymphoma
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
The partnership will capitalize on the combined capabilities of the two organizations
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Bridging the gap between histopathology and molecular pathology
Subscribe To Our Newsletter & Stay Updated